[The role of extracellular domain of human 4-1BBL in regulating activities of human peripheral blood lymphocytes in vitro].
OBJECTIVE
To investigate the role of the extracellular domain of human 4-1BBL (ex4-1BBL) in regulating the in vitro activities of peripheral blood lymphocytes (PBL).


METHODS
Viable cells were quantified with Trypan-blue exclusion assay. CytoTox 96 Nonradioactive Cytotoxicity Assay Kit was used for measuring LDH levels of supernatant. ELISA kit was used for measuring IL-2 level. In vitro cytotoxity of PBL combined with anti-CD3/anti-Pgp bispecific diabody plus ex4-1BBL was analyzed with CytoTox 96 nonradioactive method.


RESULTS
Ex4-1BBL can increase the proliferation of PBL, reduce cell death, promote IL-2 secretion, and the experimental group with ex4-1BBL showed obviously enhanced cytotoxic effect toward K562/A02 cells.


CONCLUSIONS
Ex4-1BBL may be an important adjuvant for improving activities of PBL.
Guo
Hong-xing
HX
State Key Laboratory of Experimental Hematology, Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. kuohx@yahoo.com
Cheng
Xin
X
Su
Ye
Y
Fan
Dong-mei
DM
Shao
Xiao-feng
XF
Xu
Yuan-fu
YF
Yang
Chun-zheng
CZ
Xiong
Dong-sheng
DS
D053330:4-1BB Ligand / Q000494:pharmacology*; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D049109:Cell Proliferation / Q000187:drug effects*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006801:Humans; D020014:K562 Cells; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D008819:Mice, Nude; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000276:immunology
D053330:4-1BB Ligand; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9; C456519:visilizumab